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Abstract
Introduction: Endometrial carcinoma is the one of the leading causes of terminal
cancer death in women, and the best way to solve it is through an early
diagnosis. Serum proteomic profiling is a promising approach to classify disease
versus normal and matrix-assisted laser desorption/ionization time of flight
mass spectrometry (MALDI-TOF). This analysis is a new potential tool for the
diagnosis of human diseases. The objective of our study was to assess the
feasibility of mass spectrometry, based on serum proteomic pattern for the
discrimination of endometrial carcinoma patients from healthy control patients.
Material and methods: By using 30 pre-operative endometrial carcinoma serum
samples and 30 healthy controls, we generated MALDI-TOF protein profiles,
established the serum detection model, and analyzed the data. Furthermore,
we validated the data and got the total sensitivity (97.6%) and specificity (100%),
which could classify all the samples well and demonstrated the high, significant
separation ability.
Results: Our results indicated that high sensitivity and specificity classify
endometrial carcinoma by the serum detection model and showed the potential
usefulness of serum protein profiles.
Conclusions: From these results, we could tell that MALDI-TOF MS is a potential
tool for diagnosing diseases by the use of serum samples and will be widely
used in the future for clinical work.
Key words: serum proteomic analysis MALDI-TOF endometrial carcinoma serum
detection model.
Introduction
Endometrial carcinoma is the third most common cause of gynecologic
cancer death, only behind ovarian and cervical cancer, and occurs only in
females [1]. Endometrial carcinoma occurs in both premenopausal (about
25%) and postmenopausal women (about 75%).The most commonly
affected age group is between 50 and 59 years [2]. The 5-year survival rate
for endometrial cancer is usually as follows: 95% for stage 1, 50% for
stage 2, 30% for stage 3, less than 5% for stage 4 [1]. There is a better
probable outcome associated with this form of cancer as opposed to other
types of gynecological cancers, such as cervical or ovarian cancer. In the
United States, there are over 35,000 women diagnosed each year [3].
During the past two decades, the incidence of endometrial carcinoma has
been improving steadily in China.
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The common signs and symptoms of
endometrial carcinoma are usually include the
followings: abnormal uterine bleeding, abnormal
menstrual menstrual periods, bleeding between
normal periods in premenopausal women aged over
40, anemia caused by chronic loss of blood, lower
abdominal pain or pelvic cramping, and thin white
or clear vaginal discharge in postmenopausal
women [4-6]. Additionally, there are several risk
factors for endometrial carcinoma such as high
levels of estrogen, endometrial hyperplasia, obesity,
hypertension, polycystic ovary syndrome, nulliparity,
infertility, early menarche, late menopause,
tamoxifen, high intake of animal fat, family history,
phenotype characteristics etc [7, 8].
Screening for endometrial carcinoma is always
not as easy as screening for cervical cancer because
the uterine cavity is well above the cervix. A pelvic
examination is frequently normal, especially in the
early stages of disease. Changes in the size, shape
or consistency of the uterus and its surrounding
and supporting structures may exist when the
disease is more advanced.
The traditional diagnostic method is endometrial
curettage. Both endometrial and endocervical
material should be sampled. If endometrial
curettage does not yield sufficient diagnostic
material, we need a dilation and curettage for
diagnosing the cancer.
Recently, the TruTest has been introduced as 
a new method of testing. It uses the small flexible
Tao Brush to brush the entire lining of the uterus.
This method is less painful than the usual pipelle
biopsy and just like of procuring enough tissue for
testing. As it is simpler and less invasive, the TruTest
can be performed as often, and at the same time
as a routine Pap smear, and now is allowed to use
for early detection and treatment.
The tumor marker CA-125 is sometimes checked,
since this can predict advanced stage disease [9].
During the development of proteomic study, the
proteomic profiles generated by mass spectrometry
have been thought of as potential tools for the early
diagnosis of cancer and other diseases. Different
protein profiles may be associated with varying
responses to therapeutics. It has been postulated
that on the basis of the presence (or absence) of
multiple low-molecular-weight serum proteins using
time of flight mass spectrometry technologies,
biomarkers can be identified [10-13]. Although the
data from these studies are encouraging, critical
notes have been made on both study design and
experimental procedures for proteomic profiling [14-
16]. They are the substances that can be found in
abnormal amounts in the blood, urine, or tissues of
some patients with cancer. Additionally, they can
be used to help diagnose cancer, predict a patient’s
response to particular therapies, check a patient’s
response to treatment, or determine if cancer has
returned. Researchers continue to study tumor
markers and to develop more accurate methods to
detect, diagnose, and monitor cancer. For this
reason, we hope to use proteomic techniques to
find the best way for the early diagnosis of
endometrial carcinoma. And at the very beginning
of our research, we optimized of the conditions with
MALDI-TOF MS, choosing the best kind of magnetic
beads for the pre-analysis of the disease and
normal serum samples [17].
The objective of this study was to assess the
feasibility of applying mass spectrometry for the
profiling of serum proteomic profiles in endometrial
carcinoma patients from healthy control individuals,
and to find some new early potential biomarkers
and aspire to do something to help carry out the
high sensitivity and specificity of early detection of
endometrial carcinoma.
Material and methods
Patients
The study protocol was approved by the
Research Ethics Committee of Chinese PLA General
Hospital and with each patient’s agreement. Serum
samples were obtained from a total of 30 endo-
metrial carcinoma patients the day before surgery.
Surgical specimens and pathological validation
historically confirmed endometrial carcinoma. The
median age of the female patient group was 
50 years old, with patients admitted from
November 2006 until May 2008 in our hospital. The
healthy control volunteers group consisted of 
30 individuals. The median age of the healthy
female control group was 47 years old, and all were
recruited from our hospital healthy check center.
Chemicals and calibrators
Gradient-grade alcohol and acetone were
obtained from J.T. Baker; p.a.trifluoroacetic acid and
ammonium acetate were purchased from Sigma-
Aldrich. The peptide calibrator containing
angiotensin II, the protein calibrator, and the matrix
α-cyano-4-hydroxycinnamic acid (HCCA) were
purchased from Bruker Daltonics GmbH. For
magnetic bead preparations, we used 0.2 ml of
polypropylene tubes (8-tube strips) from Axygen
Company. Multifly needle sets and polypropylene
vacuette without anticoagulants (EDTA, heparin and
citrate) were obtained from BD Company.
Blood samples
The blood samples were processed according to
a standardized protocol. After sample collection, the
vacuette serum (collected in a red-top glass tube
containing no preservatives or anticoagulant) were
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allowed to clot or to sediment at room temperature
(about 25°C) for at least half an hour and then
centrifuged at 1500 g for 15 min. Samples were
divided in 100 µl aliquots and immediately frozen
at –80°C, refrigerated until use; for proteomic
fractionation, samples were thawed at room
temperature (about 25°C) for 15 min and processed
immediately.
Proteomic fractionation (isolation of peptides)
By using functionalized magnetic bead-based
kits, serum samples were fractionated (ClinProt Kits,
Bruker Daltonics Inc. Germany). Magnetic beads
were designed to capture proteins and peptides
from serum and to obtain specific profiles based on
cationic exchange chromatography. They were used
according to the manufacturer’s protocols. As
recommended, we added 5 µl WCX magnetic beads
with 10 µl of a binding solution in a 0.2 ml
polypropylene PCR tube. Then, we added 5 µl of the
sample and mixed thoroughly by pipetting up and
down several times, incubated the tube for 5 min,
and separated the unbound solution using 
a magnetic bead separator. After magnetic bead
separation and three washings, the bound proteins
or peptides in the serum samples were eluted from
the magnetic beads according to the manufacturer’s
instructions (Profiling Kit WCX and Profiling, Bruker
Daltonics GmbH, Germany). A portion of the sample
was diluted 1 : 10 in a solution containing HCCA 
(0.6 g/l in 2 : 1 ethanol: acetone). Then, 1 µl of the
resulting mixture was spotted onto the AnchorChip
target (Bruker Daltonics Inc., CA) and allowed to air
dry for approximately 5 min at room temperature.
Usually, each sample for each conditioned
experiment was conducted three times.
MS analysis (protein profiling)
For the proteomic analysis, we used a linear
MALDI-TOF mass spectrometer (Microflex; Bruker
Daltonics) with the following settings: ion source 1,
20 kV; ion source 2, 18.40kV; lens, 7.50 kV; pulsed
ion extraction, 120 ns; nitrogen pressure, 1700-2000
mbar. Ionization was achieved by irradiation with 
a nitrogen laser (λ = 337 nm) operating at 25 Hz.
The mass calibration was performed with the
calibration mixture of peptides and proteins in 
a mass range of 1000-10000 Da. We measured 
3 MALDI preparations from each magnetic bead
fraction. For each MALDI spot, 400 spectra were
acquired in analysis (50 laser shots at 8 different
spot positions). 
To increase the detection sensitivity, we usually
use higher energy to shot the spot positions at first
and then a lower energy to shot again and then save
the spectra, which can remove the excess matrix
with higher laser power before data acquisition.
Data processing 
The spectra of all signals with a signal-to-noise
(S/N) ratio > 5 in a mass range of 1000-10000 Da
obtained from all of the samples, were analyzed by
using ClinProTools software for spectrum processing
and generation of proteomic fingerprints. Only the
spectra obtained from WCX magnetic beads were
used in the analysis of this report. We used the
ClinProTools bioinformatics software (Ver. 2.1; Bruker
Daltonics) for proteomic pattern recognition. 
To increase the accuracy, we used the average
of eight spots representing one serum sample.
Specifically, all spectra were normalized to their own
total ion count (summation of peak areas) and
recalibrated using the most prominent peaks,
followed by baseline subtraction, peak defining, and
calculation of peak intensities and areas. 
Then, we calculated the mean value of peak
intensity, SD and CV (%) for each corresponding
peak among the endometrial carcinoma and
healthy control groups. The degree of variation on
the basis of the whole spectrum was determined
by calculating the CV values for some prominent
peaks of the samples. We defined p < 0.01 as a si-
gnifi  cant difference.
Results
The whole correlation of mass spectrum
At first, before pre-processing and further
analysis of each sample’s mass spectra, all eight
spots were measured for each sample. The
simulated two-dimensional gel electrophoresis
result was shown in Figure 1 to see the correlation
of the whole correlation of the groups. From this,
we determined that the coherence of each group
performed very well, which laid the best foundation
for our further research and analysis.
Then, we checked all the original mass spectra
of the two groups, the endometrial carcinoma group
and the healthy control group, to confirm the whole
coherence of the raw mass data. From this result
in Figure 2, we determined that the coherence of
the raw mass data was promising enough to
continue our further data analysis.
Establishment of the endometrial carcinoma
detection model
We chose 30 endometrial carcinoma patients and
30 patients with gender and age-matched healthy
controls to establish the endometrial carcinoma
serum detection model. With the help of ClinProTools
software, we established the sample distribution
coordinate by two differential proteins or peptides,
which were the pk14, 1012.6 in the vertical axis, and
the pk115, 6052.9 in the horizontal axis. The result
of that was shown in Figure 3 as follows.
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From the result shown in Figure 2, we can
determine that by using these two proteins or
peptides, there was no overlap region, which
showed that we could differentiate the samples in
the two groups well.
The prominent expression of proteins 
or peptides in the endometrial carcinoma
serum detection model
There were a total of 147 peaks found in the
endometrial carcinoma and healthy control group.
After the statistical analysis in the established
endometrial carcinoma serum detection model, we
found that some proteins or peptides were higher
expressed and some were lower expressed in the
disease group. We can easily differentiate the
endometrial carcinoma and healthy control samples
by using either one of these proteins or peptides
or using some of them together. If we use all these
proteins or peptides together as a combined one,
the sensitivity and specificity is much higher than
the result that uses each individually. 
From all the peaks found in the disease and
healthy control group, peak 40, 1946.71 m/z shown
below in Figure 4 was higher expressed in the
endometrial carcinoma group than expressed in the
healthy control group, and peak 45, 2084.06 m/z
just as peak 40 shown below in Figure 5 was also
higher expressed in the endometrial carcinoma
group than in the healthy control group.
But peak 114, 5931.22 m/z (see in Figure 6) was
lower expressed in the endometrial carcinoma
group than in the healthy control group. And the 
p value in all these three proteins or peptides were
< 0.01, with great significance.
We thought all the proteins or peptides used to
establish the endometrial carcinoma serum
detection model were the prominent ones, this may
warrant further investigation in the future to know
to determine more specific roles.
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Figure  1.  The simulated two-dimensional gel
electrophoresis result in endometrial carcinoma
group and healthy control group (the upload –
healthy control group, the download – the
endometrial carcinoma group)
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Figure 2. The whole mass spectra of the endometrial
carcinoma and healthy control group (red –
endometrial carcinoma group, green – healthy
control group)
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Figure 3. The sample distribution map of endometrial
carcinoma samples and healthy control individuals
(red – endometrial carcinoma samples, green –
healthy control individuals)
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Figure 4. The average peak expression of peak 40,
1946.71 m/z in the endometrial carcinoma and the
healthy control group (red – endometrial carcinoma
group, green – healthy control group)Arch Med Sci 2, April / 2010 249
Based on these results, we list some of the
prominent proteins or peptides that were higher or
lower expressed in the endometrial carcinoma
model and with the satisfaction of p value < 0.01
and DAve > 80 as great significance. Then, we list
these differential proteins or peptides found in the
peak list in Table I.
And from the results in Table II, we could know
that most of the differential proteins or peptides
found in the detection model were higher expressed
in the endometrial carcinoma group than those in
the healthy control group.
The MS data analysis by algorithm
With the help of ClinProTools software and the
genetic algorithm (GA) method, we used four
characteristic peaks that were pk61, 2902.49 m/z,
pk100, 5068.89 m/z, pk115, 6052.9, and pk128,
7010.58 m/z as combined factors to establish the
endometrial carcinoma serum detection model, and
determined that the sensitivity and the specificity
was 97.62 and 100%, respectively.
Then, we used the other two algorithm methods:
supervised neural network (SNN) and quick
classifier (QC) to analyze the MS data. The result
showed that there were ten differential proteins or
peptides used in the SNN method, and the
sensitivity was 92.02% and the specificity was
100%. In the QC method, there were only two
proteins or peptides used to classify the two group
samples, they were pk14, 1012.6 m/z and pk16,
6093.12 m/z and got the sensitivity was 92.86% and
the specificity was 93.75%, respectively.
From these results, we created a table to
compare the proteins or peptides being used in
these three algorithm methods, the results were
shown in Table III as follows.
From the results in Table III, we could propose
that in the GA method, four proteins or peptides
were used to classify all the samples in the
endometrial carcinoma group and healthy group;
in the SNN method, about ten differential proteins
or peptides were used to do the classification; but
in the QC method, just two proteins or peptides
were used to do the classification. The same protein
pk115, 6052.9 was used in both the GA method and
SNN method and pk116, 6093.12 was also used to
do the classification in the SNN method and QC
method. But no same proteins or peptides were
used in the GA and QC method and no same
proteins or peptides were used to do the
classification in all three-algorithm methods.
Finally, by using different proteins or peptides to
do the classification we obtained different
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Figure 5. The average peak expression of peak 45,
2084.06 m/z in the endometrial carcinoma and the
healthy control group (red – endometrial carcinoma
group, green – healthy control group)
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Figure 6. The average peak expression of peak 114,
5931.22 m/z in the endometrial carcinoma and the
healthy control group (red – endometrial carcinoma
group, green – healthy control group)
Peak  Peak Mass DAve P value
number index
1 67 3243.51 +87.08 < 0.01
2 55 2662.68 +119.58 < 0.01
3 45 2084.06 +160.63 < 0.01
4 59 2864.98 +89.21 < 0.01
5 40 1946.77 +134.65 < 0.01
6 92 4285.06 +185.73 < 0.01
7 114 5931.22 –111.97 < 0.01
Table I.  Higher or lower expressed proteins or
peptides in the endometrial carcinoma serum
detection model
+ expressed higher in endometrial carcinoma group, – expressed
lower in endometrial carcinoma group
Algorithm method Sensitivity [%] Specificity [%]
GA method 97.60 100
SNN method 92 100
QC method 92.90 93.80
Table II. The sensitivity and specificity in the three
algorithm methods250 Arch Med Sci 2, April / 2010
sensitivity and specificity in the three algorithm
methods, and listed the results in Table II.
From the results in Table II we found that by using
different proteins or peptides as the combination in
these three algorithm method, we could get different
sensitivity and specificity, and all the sensitivity and
the specificity were of great results of more than
90%. In the QC method, we used only two proteins
or peptides that were pk14, 1012.6 and pk116,
6093.12, and got the sensitivity and specificity were
92.90 and 93.80%, respectively which may tell us
that we may can use just these two proteins or
peptides to classify the samples in the endometrial
carcinoma and healthy control group.
The Principle Component Analysis 
In order to get more information about the
variation within the serum endometrial carcinoma
model generation classes and the homogeneity or
heterogeneity of a spectra set, we can use a PCA.
An external MATLAB software tool carried out the
PCA. By the result of the PCA in Figure 7, we can
identify the samples distribution in the model.
From the results in Figure 7, we could potentially
know the endometrial carcinoma and healthy
control samples distribution with the Principle
Component Analysis.
Discussion
Nowadays, endometrial carcinoma is becoming
one of the common malignancy tumors and strongly
threatening women’s health as its incidence is
growing at a rapid rate. The high risk factors of that
include menopause delay, obesity, diabetes, family
factors, and so on. For most cancers, endometrial
carcinoma survival rates mainly depend on the early
detection and early diagnosis of it. But up to now,
there are no satisfactory biomarkers that could deal
with this difficult task. In recent years, there have
been great changes in the proteomic research field,
new proteomic technologies have brought the hope
to discovering differences between disease and
healthy control in the proteomic pattern and the
early cancer-specific biomarkers in the complex
biologic samples.
The development of MALDI-TOF MS gives us an
effective tool for protein profiling study and biomarker
identification. The usual approaches for the discovery
of disease-related proteins or peptides are two-
dimensional polyacrylamide gel electrophoresis (2D-
PAGE) and the mass spectrometry. However, there are
some limitations in the classical methods such as
extensive sample preparation, difficult pre-extraction
or fractionation, the contaminants of samples etc. All
these will hinder the use for high-throughput
screening of disease from healthy ones. MALDI-TOF
MS has overcome many of these limitations. By using
this method, we can successfully find differential
expression between disease and normal groups, and
can discover potential serum diagnostic biomarker
for future clinical work. MALDI-TOF MS has been
widely used for breast cancer [18], lung cancer [13],
bladder cancer [19], liver cancer [20], colon cancer [21],
Feng Qiu, Yan H. Gao, Chao G. Jiang, Ya P . Tian, Xue J. Zhang
GA method SNN method QC method
Peak number Mass Peak number Mass Peak number Mass
128 7010.58 53 2585.78 14 1012.6
115 6052.9 80 3938.26 116 6093.12
100 5068.89 67 3243.51
61 2902.49 26 1501.02
116 6093.12
105 5224.33
25 1451.97
131 7606.66
115 6052.9
18 1083.74
Table III. Proteins or peptides used for classification in the three algorithm methods
600
400
200
0
–200
–400
–600
–800
1000
500
0
0
1000
2000
–500
–1000  –2000 
–1000 PC2
PC3
PC1
Figure  7. Samples distribution in the Principle
Component Analysisovarian cancer [22] and gastric cancer [23]. Little has
been reported about the proteomic study on
endometrial carcinoma.
In our study, we chose 30 endometrial carcinoma
patients and 30 with gender and age-matched
healthy controls to establish the endometrial
carcinoma serum detection model. With the help
of ClinProTools software, we can just use two
differential proteins or peptides pk14, 1012.6 and
pk115, 6052.9 to classify all the samples, and tell us
which was disease and which was healthy. Despite
this, we still found some proteins or peptides
differential expressed in the cancer and healthy
control group. Some were highly expressed in the
endometrial carcinoma group, and some were lower
expressed in them, such as peak 40, 1946.71 m/z,
peak 45, 2084.06 m/z, peak 114, 5931.22 m/z, peak
67, 3243.51 m/z, peak 59, 2864.98 m/z etc, and the
p value were all < 0.01, with great significance. Then,
by using three algorithm methods (GA, SNN and
QC), we obtained the sensitivity and specificity
analysis of our serum endometrial carcinoma
model, and the results were very prosperous, the
sensitivity and specificity were both more than 90%.
Such results can lead the way to positively identify
the candidate proteins or peptides markers found
in the study to make a further understanding of the
mechanisms of endometrial carcinoma genesis and
development. 
Though, to some degree, the numbers of
samples analyzed in our study limited the validity
of the results. We will do further independent and
blinded validation study with more serum samples
to confirm the former results. In the future, we will
perform a comparison study between early-stage
cancer with later-stage cancer to discover the
potential biomarkers to monitor the recurrence and
metastasis of endometrial carcinoma. Then, we will
go on to study the observation of serum proteomic
profile expression following the development of the
disease and still keep on working for the
identification and validation of new biomarkers.
In conclusion, by the use of proteomic approach
MALDI-TOF MS, with the combination of bio-
informatics tools, we can find the differences in the
endometrial carcinoma and the matched healthy
control group and discover some new potential bio  -
markers. With the help of the panel of differential
proteins or peptides found in our research, we could
achieve the high sensitivity and specificity for the
detection of endometrial carcinoma. In future work,
we may attempt to validate and identify these
potential biomarkers. From our research, we could
make a conclusion that MALDI-TOF MS is a novel,
high-throughput, sensitive, highly predictive and
rapid method for the early detection, early diagnosis
and prediction of endometrial carcinoma and will
be widely used in future clinical screening work.
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